As Principal, Autoimmune and Inflammatory Disease Co-Lead, Commercial BioConsulting, Danielle co-leads the rapidly growing autoimmune and inflammatory disease practice. Within this space, she is responsible for helping early-stage companies more quickly or efficiently achieve value inflection via a range of projects, including indication or target prioritization and sequencing, therapeutic area growth strategy, identification and evaluation of partnering opportunities, and commercial market assessments.
Prior to joining the firm in 2011, Danielle spent 5 years as a scientist at an emerging biotech company focused on the oral delivery of peptide therapeutics for metabolic and autoimmune bone diseases. Danielle also supported the business development team by performing competitive intelligence exercises to identify potential licensing partners, as well as evaluating competitors in the peptide therapeutic space.
Danielle holds a Master's Degree in Molecular Biology and an MBA from Rutgers University. Her Masters research focused on the NAD-dependent deacetylase, sirtuin-1, and its activity in colon, breast, and pancreatic cancer. She holds a BS in Biology from the College of New Jersey.